ストックスクリーナーアプリを入手
5.15
3.00%
0.1499
前日終値:
$5.0001
開ける：
$5.01
24時間の取引高:
10,670
Relative Volume:
0.37
時価総額：
$27.54M
収益：
-
当期純損益:
$-16.35M
株価収益率:
-2.1639
EPS:
-2.38
ネットキャッシュフロー:
$-11.88M
1週間 パフォーマンス:
+5.32%
1か月 パフォーマンス:
-6.36%
6か月 パフォーマンス:
-21.97%
1年 パフォーマンス:
+108.50%
1日の値動き範囲:
$4.866
$5.20
1週間の範囲:
$4.63
$5.20
52週間の値動き範囲:
$2.38
$11.79
Lipocine Inc Stock (LPCN) Company Profile
名前
Lipocine Inc
セクター
電話
801 994 7383
住所
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
LPCN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| LPCN | 5.15 | 27.54M | 0 | -16.35M | -11.88M | -2.38 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-06-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-12-10 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2018-01-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-01-11 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2017-12-08 | 再開されました | H.C. Wainwright | Buy |
| 2016-10-07 | 開始されました | H.C. Wainwright | Buy |
| 2015-07-22 | 開始されました | ROTH Capital | Buy |
| 2015-06-23 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Lipocine Inc (LPCN) 最新ニュース
Lipocine's LPCN 1148 Shows Breakthrough Results in Liver Disease Clinical Trial | LPCN Stock News - StockTitan
Lipocine (NASDAQ:LPCN) Announces Financial Results for the Quarter Ended September 30, 2024 - Defense World
When the Price of (LPCN) Talks, People Listen - Stock Traders Daily
Lipocine: Q3 Earnings Snapshot - CT Insider
Lipocine Inc. (LPCN) Quarterly 10-Q Report - Quartz
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024 - PR Newswire
Lipocine Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lipocine (NASDAQ:LPCN) Presents Positive Data on LPCN 2401 at Obesity Society Conference - Defense World
Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference - GuruFocus.com
Lipocine inks deal to bring TLANDO to South Korea - Investing.com
Lipocine Partners With SPC Korea For TLANDO In South Korea - Contract Pharma
Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea - Morningstar
Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study i - GuruFocus.com
Trading (LPCN) With Integrated Risk Controls - Stock Traders Daily
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1 - GuruFocus.com
Lipocine Announces Completion of Dosing in Pivotal Study of Post - GuruFocus.com
(LPCN) Trading Signals - Stock Traders Daily
Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Bod - GuruFocus.com
Lipocine reports promising oral brexanolone study results By Investing.com - Investing.com Australia
Lipocine reports promising oral brexanolone study results - Investing.com India
Lipocine Enters Exclusive Supply And Distribution Agreement With Pharmalink - Contract Pharma
Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results - PR Newswire
Lipocine signs supply and distribution agreement with Pharmalink for Tlando - Yahoo Finance
Lipocine partners with Pharmalink for GCC distribution of TLANDO - Investing.com
Lipocine partners with Pharmalink for GCC distribution of TLANDO By Investing.com - Investing.com Nigeria
Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries - PR Newswire
Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024 - Citizentribune
Alliance Global Partners Initiates Coverage on Lipocine (NASDAQ:LPCN) - Defense World
Lipocine (NASDAQ:LPCN) Upgraded to Buy at StockNews.com - Defense World
‘Lubber Pandhu also has strong emotions beyond cricket’ - DTNEXT
Louisiana-Pacific director sells $245,750 in company stock By Investing.com - Investing.com Canada
PLRX’s 52-Week Rollercoaster: From $10.29 to $19.62 – What’s Next for Investors? - The InvestChronicle
Health Check: Paradigm receives FDA guidance on proposed trial for dodgy knees - Stockhead
Pliant Therapeutics (NASDAQ:PLRX) Sees Large Volume Increase - MarketBeat
Liquidia Corp [LQDA] Investment Guide: What You Need to Know - Knox Daily
MediPharm Labs Corp. - Baystreet.ca
A stock that deserves closer examination: Lipella Pharmaceuticals Inc (LIPO) - US Post News
PLRX’s latest rating updates from top analysts. - Knox Daily
Labcorp Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Pliant Therapeutics (NASDAQ:PLRX) Shares Gap Up to $12.00 - MarketBeat
Prudential PLC Sells 7,956 Shares of Laboratory Co. of America Holdings (NYSE:LH) - MarketBeat
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Research Analysts Set Expectations for Pliant Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:PLRX) - Defense World
Lipocine Inc. filed SEC Form 8-K: Financial Statements and Exhibits - Quantisnow
Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek® - Kilgore News Herald
Lipocine (NASDAQ:LPCN) Downgraded by StockNews.com to “Hold” - Defense World
Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference – Company Announcement - Financial Times
Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Sarcopenia Market to Grow Positively at a Paltry CAGR During - openPR
StockNews.com Lowers Lipocine (NASDAQ:LPCN) to Hold - Defense World
Lipocine (NASDAQ:LPCN) Raised to Buy at StockNews.com - Defense World
Lipocine Inc (LPCN) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
2.08%
大文字化:
|
ボリューム (24 時間):